Xilio Therapeutics (XLO) AI Stock Analysis

• Market Cap: $39.09M
• Dividend Yield: N/A
• Average Volume (3M): 214.45K
• Price to Earnings (P/E): ―
• Beta (1Y): -0.21
• Revenue Growth: N/A
• EPS Growth: 53.92%
• Country: US
• Employees: 64
• Sector: Healthcare
• Sector Strength: 74
• Industry: Biotechnology
• EPS (TTM): -1.28
• Shares Outstanding: 51,775,394
• 10 Day Avg. Volume: 202,592
• 30 Day Avg. Volume: 214,452
• PEG Ratio: N/A
• Price to Book (P/B): N/A
• Price to Sales (P/S): 0.00
• Price to Cash Flow (P/CF): 0.00
• P/FCF Ratio: 0.00
• Enterprise Value/Market Cap: -0.07
• Enterprise Value/Revenue: N/A
• Enterprise Value/Gross Profit: -0.45
• Enterprise Value/Ebitda: N/A
• 1Y Price Target: $4.50
• Price Target Upside: 492.11% Upside
• Rating Consensus: Strong Buy
• Number of Analyst Covering: 3

Xilio Therapeutics receives a moderate score due to a mix of promising strategic partnerships and ongoing financial challenges. The partnership with AbbVie is a notable positive, providing potential financial and strategic benefits. However, the company's current lack of profitability and negative cash flow impact the overall evaluation. Technical analysis indicates short-term momentum, but longer-term trends remain a concern. The valuation reflects the company's current unprofitability.

Positive Factors

Clinical Trial Results

The initial Phase II data for the vilastobart and atezolizumab combination in MSS CRC patients shows a higher objective response rate compared to salvage therapies.

Financial Stability

Ended 4Q24 with ~$55M in cash combined with $52M in upfront payments from collaboration with Abbvie expected to support operations into 1Q26.

Strategic Collaboration

Xilio has announced a growing focus on developing T-cell engagers using its masking platform, which has attracted collaboration with AbbVie.

Negative Factors

Clinical Trial Challenges

XTX-202 was being tested in a Phase I/II trial with expansion cohorts in melanoma/RCC. However, the monotherapy program was ultimately discontinued due to modest efficacy.

Development Program Setbacks

The monotherapy program for XTX-202 was ultimately discontinued due to modest efficacy.

Operational Challenges

Current cash supports operations through 2Q25, providing financial stability for continued development.

Xilio Therapeutics Business Overview & Revenue Model

Company Description

Xilio Therapeutics, Inc., a clinical-stage biotechnology company, develops immunotherapies to improve the immune system of cancer patients. Its checkpoint inhibitor program includes XTX101, a clinical-stage, tumor-selective anti-CTLA-4 mAb that is in Phase 1/2 clinical trials in patients with solid tumors. The company also develops cytokine programs, which comprises XTX202, a modified form of IL-2; XTX301, an IL-12 product candidate; and XTX401, an IL-15 product candidate that are masked with a protein domain to prevent binding activity until cleaved off by tumor microenvironment (TME)-associated proteases. Xilio Therapeutics, Inc. was founded in 2016 and is headquartered in Waltham, Massachusetts.

How the Company Makes Money

Xilio Therapeutics makes money primarily through the development and potential commercialization of its proprietary cancer therapies. The company invests in research and development to create innovative tumor-selective treatments, which it aims to bring to market either independently or through strategic partnerships with larger pharmaceutical companies. Revenue streams may include upfront payments, milestone payments, and royalties from licensing agreements, as well as eventual product sales pending successful clinical trials and regulatory approvals. Additionally, partnerships with other biotech or pharmaceutical firms can provide funding and resources to advance the development of its therapeutic candidates.

Xilio Therapeutics Financial Statement Overview

Summary

Xilio Therapeutics shows initial revenue generation but faces challenges with profitability and cash flow. Despite moderate financial stability, high liabilities and negative equity trends pose risks. Improving operational efficiency and cash flow is crucial.

Income Statement

Xilio Therapeutics shows a recent improvement in revenue, achieving $6.34M in 2024, up from zero in previous years. However, the company continues to operate at a loss, with negative EBIT and EBITDA margins and no net income, indicating a challenging profitability scenario.

Balance Sheet

The company maintains a relatively low debt-to-equity ratio due to its high equity levels, but its equity has been decreasing over time. The equity ratio is moderate, showing some financial stability. High liabilities relative to assets pose a risk.

Cash Flow

Free cash flow remains negative, but there was a significant cash inflow from financing activities in 2024. Operating cash flow to net income is not applicable due to the absence of net income, indicating cash flow challenges despite recent revenue.

Breakdown
Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020
Income Statement		Total Revenue
6.34M	0.00	0.00	0.00	0.00
	Gross Profit
6.34M	-1.90M	-1.85M	-1.50M	-1.06M
	EBIT
-60.58M	-79.13M	-89.15M	-75.04M	-54.56M
	EBITDA
-58.00M	-73.80M	-85.58M	-73.70M	-53.50M
	Net Income Common Stockholders
-58.24M	-76.40M	-87.30M	-74.30M	-55.22M
Balance Sheet		Cash, Cash Equivalents and Short-Term Investments
55.29M	44.70M	120.39M	198.05M	19.24M
	Total Assets
71.08M	60.93M	139.16M	218.06M	36.32M
	Total Debt
8.14M	11.46M	19.94M	20.54M	21.22M
	Net Debt
-47.15M	-33.25M	-100.45M	-177.52M	1.98M
	Total Liabilities
53.48M	24.10M	33.52M	32.63M	119.60M
	Stockholders Equity
17.60M	36.83M	105.65M	185.43M	-83.29M
Cash Flow		Free Cash Flow
-18.41M	-69.11K	-77.59M	-81.85M	-38.28M
	Operating Cash Flow
-18.38M	-68.62M	-75.72M	-80.75M	-36.09M
	Investing Cash Flow
-36.00K	-486.00K	-1.87M	-1.10M	-2.19M
	Financing Cash Flow
29.20M	-6.55M	-69.00K	260.67M	10.03M

Xilio Therapeutics Technical Analysis

• Technical Analysis Sentiment: Negative
• Last Price: 0.76
• 50DMA: Negative
• 100DMA: Negative
• 200DMA: Negative
• MACD: Negative
• RSI: Neutral
• STOCH: Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For XLO, the sentiment is Negative. The current price of 0.76 is above the 20-day moving average (MA) of 0.74, below the 50-day MA of 0.80, and below the 200-day MA of 0.90, indicating a neutral trend. The MACD of <0.01 indicates Negative momentum. The RSI at 48.76 is Neutral, neither overbought nor oversold. The STOCH value of 33.02 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for XLO.

Xilio Therapeutics Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
XLO	54 Neutral	$39.09M	―	-214.02%	―	―	53.92%
Sector *	52 Neutral	$5.28B	3.75	-42.72%	2.86%	17.70%	2.03%
CNTB	49 Neutral	$45.47M	―	-58.89%	―	―	―
LTRN	45 Neutral	$39.04M	―	-66.93%	―	―	-31.16%
FBRX	42 Neutral	$47.14M	―	-80.82%	―	―	43.64%
XFOR	39 Underperform	$24.95M	―	-102.26%	―	―	69.37%
OKYO	38 Underperform	$53.71M	―	0.00%	―	―	―

Xilio Therapeutics Corporate Events

Xilio Therapeutics Partners with AbbVie for Immunotherapy Expansion

On February 10, 2025, Xilio Therapeutics announced a collaboration and option agreement with AbbVie to develop novel tumor-activated immunotherapies. The agreement includes an upfront payment of $52 million and potential contingent payments up to $2.1 billion. AbbVie will leverage its oncology expertise alongside Xilio’s proprietary technology to advance masked T cell engagers and other immunotherapies. This collaboration positions Xilio to accelerate its technology’s expansion into next-generation therapies, potentially enhancing its market presence and providing significant financial benefits.